-
2024-516649-38-00
5
2020-12-01
Recurrent ovarian, fallopian tube or primary peritoneal cancer
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-510465-10-00
4
2025-03-10
Meningococcal immunization
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2023-505054-17-00
6
2023-09-15
metastatic TTF-1 negative lung adenocarcinoma
-
2023-508265-33-00
5
2022-10-13
Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2024-516959-40-00
4
2021-08-17
This trial evaluates the efficacy and safety of Mirvetuximab soravtans
-
2024-517761-17-00
4
2021-05-31
Multiple Myeloma
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2024-514820-18-00
4
2018-03-07
newly diagnosed glioblastoma
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2023-505762-29-00
5
2024-08-09
Virus diseases
-
2022-502124-52-00
5
2018-12-18
Advanced epithelial ovarian cancer
-
2023-508472-11-00
5
2018-06-13
Patients with early breast cancer
-
2024-518022-33-00
5
2016-07-15
Advanced Stage of Hodgkin Lymphoma